Comparative Pharmacology
Head-to-head clinical analysis: PHENERGAN VC versus PROMETHAZINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PHENERGAN VC versus PROMETHAZINE HYDROCHLORIDE.
PHENERGAN VC vs PROMETHAZINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Phenergan VC is a combination of promethazine (a phenothiazine derivative with antihistaminic, sedative, antiemetic, and anticholinergic effects) and phenylephrine (a sympathomimetic amine that acts as a decongestant via alpha-1 adrenergic receptor agonism). Promethazine antagonizes H1 receptors, thereby suppressing allergic reactions and motion sickness. Phenylephrine causes vasoconstriction in the nasal mucosa, reducing congestion.
Promethazine is a phenothiazine derivative that acts as a histamine H1 receptor antagonist, blocking the effects of histamine at H1 receptors. It also has anticholinergic, antiemetic, sedative, and antidopaminergic properties.
10-20 mL orally every 4-6 hours as needed; each 5 mL contains 6.25 mg promethazine HCl and 5 mg phenylephrine HCl.
25-50 mg intramuscular or intravenous injection every 4-6 hours as needed; also 12.5-25 mg orally every 4-6 hours.
None Documented
None Documented
9-16 hours; prolonged in hepatic impairment.
Terminal elimination half-life is 10-19 hours in adults; prolonged in hepatic impairment (up to 30+ hours) and in elderly.
Renal: 70-80% as metabolites; biliary/fecal: 20-30%.
Primarily hepatic metabolism; renal excretion of metabolites accounts for <1% of unchanged drug; biliary/fecal excretion of metabolites ~70-80%.
Category C
Category A/B
Antihistamine/Decongestant Combination
Antihistamine / Antiemetic